Generic Medicine Info
Should be taken with food. Take w/ meals or up to 2 hr after meals.
Hypersensitivity. Congenital or documented acquired QT prolongation, complete AV block (including patients at high risk) w/o implanted pacemakers, electrolyte disturbance (particularly uncorrected hypokalaemia), clinically relevant bradycardia or heart failure w/ reduced left-ventricular ejection fraction, history of symptomatic arrhythmia. Severe hepatic impairment. Lactation. Concomitant admin w/ drugs that prolong QT or PR interval, sedative/hypnotics (triazolam, oral midazolam), HMG-CoA reductase inhibitors (simvastatin, lovastatin), ergot alkaloids, rifampicin, quetiapine, alfuzosin.
Special Precautions
Patient w/ haemophilia A and B, pre-existing conduction system abnormalities. Mild to moderate hepatic or severe renal impairment. Pregnancy. Monitoring Parameters Monitor ECG, serum K and Mg levels, triglycerides, cholesterol, viral load, CD4 count and glucose.
Adverse Reactions
GI disorders (e.g. abdominal pain, nausea, vomiting, flatulence, diarrhoea), fatigue, anaemia, alopecia, anorexia, increased appetite, asthenia, constipation, dizziness; dry lips, mouth and skin; dyspnoea, dyspepsia, eczema, headache, decreased libido, muscle spasm, malaise, peripheral neuropathy, paraesthesia, rash, pruritus, sleep disturbances, taste disorders; increased liver enzyme, blood amylase, bilirubin and creatinine levels; reduced Hb, platelet, lymphocyte and WBC counts; immune reconstitution syndrome, accumulation or redistribution of body fat, metabolic abnormalities (e.g. hypertriglyceridaemia), osteonecrosis. Abscess, angina tonsillaris, candidiasis, cellulitis, herpes simplex, herpes zoster, bacterial or mycotic infections, influenza, moniliasis. Rarely, acute myeloid leukaemia, allergic reactions, ascites, bullous skin eruptions, intestinal obstruction, jaundice, portal HTN, seizures, polyarthritis, attempted suicide.
Potentially Fatal: Hypersensitivity (e.g. anaphylactic reaction, Stevens-Johnson syndrome), thrombocytopenia, haemolytic anaemia, pancreatitis, nephrolithiasis.
Drug Interactions
May increase plasma concentration of fusidic acid. Increased risk of bleeding w/ anticoagulants (e.g. rivaroxaban). May alter plasma concentrations of warfarin.
CIMS Class
ATC Classification
J05AE01 - saquinavir ; Belongs to the class of protease inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on saquinavir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in